{
    "name": "Ebola Zaire vaccine",
    "comment": "Rx",
    "other_names": [
        "Ervebo"
    ],
    "classes": [
        "Vaccines",
        "Live",
        "Viral"
    ],
    "source": "https://reference.medscape.com/drug/ervebo-ebola-zaire-vaccine-4000027",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women, and human data available from clinical trials are insufficient to establish the presence or absence of vaccine-associated risk during pregnancy",
            "Consider the woman’s risk of exposure to Zaire ebolavirus before vaccination"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Fetal and neonatal outcomes are universally poor among pregnant women infected with Zaire ebolavirus",
                    "Majority of such pregnancies end in miscarriage or stillbirth",
                    "In pregnancies where live birth does occur, neonates generally do not survive",
                    "Potential for transmission of the vaccine virus from mother to the fetus/neonate is unknown"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Human data are not available to assess the effects on milk production, its presence in breast milk, or its effects on the breastfed child",
            "Consider developmental and health benefits of breastfeeding along with the mother’s clinical need and any potential adverse effects on the breastfed child or from the underlying maternal condition",
            "For preventive vaccines, the underlying condition is susceptibility to disease prevented by the vaccine"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to any component of the vaccine, including rice protein"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "There were 2 reports of anaphylaxis; monitor for signs and symptoms of hypersensitivity reactions following vaccination; appropriate medical treatment and supervision must be available in case of an anaphylactic event following administration ",
                "Vaccination may not protect all individuals; vaccinated individuals should continue to adhere to infection control practices to prevent Zaire ebolavirus infection and transmission",
                "Safety and effectiveness have not been assessed in immunocompromised individuals; weigh the risk of vaccination in immunocompromised individuals against the risk of disease due to Zaire ebolavirus",
                "Vaccine virus RNA has been detected by RT-PCR in blood, saliva, urine, and fluid from skin vesicles of vaccinated adults; transmission of vaccine virus is a theoretical possibility"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Interference with laboratory tests ",
                        "Following vaccination, individuals may test positive for anti-Ebola glycoprotein (GP) antibody and/or Ebola GP nucleic acid or antigens",
                        "GP-based testing may have limited diagnostic value during period of vaccine viremia, in the presence of vaccine-derived Ebola GP, and following antibody response to the vaccine"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abrocitinib",
            "description": {
                "common": "abrocitinib decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administration of live vaccines is not recommended during abrocitinib treatment and immediately before or after treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anifrolumab",
            "description": {
                "common": "anifrolumab decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Before initiation, update immunization according to current guidelines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atoltivimab/maftivimab/odesivimab",
            "description": {
                "common": "atoltivimab/maftivimab/odesivimab decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Ebola monoclonal antibodies may interfere with immune response of live vaccines. Refer to vaccine guidelines for vaccination timing during and following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ciltacabtagene autoleucel decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine decreases effects of Ebola Zaire vaccine by pharmacodynamic antagonism. Contraindicated. Avoid live vaccines in immunocompromised patients due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Avoid live vaccines for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, Ebola Zaire vaccine.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ofatumumab SC for live or live-attenuated vaccines, and whenever possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live-attenuated vaccines with ozanimod during treatment and for up to 3 months after discontinuing ozanimod. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live attenuated vaccines at least 1 month before initiating, during, and for 1-2 weeks after treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "satralizumab",
            "description": {
                "common": "satralizumab decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. ive vaccines are not recommended during treatment. Administer all immunizations according to immunization guidelines. At least 4 weeks before initiating for live or live-attenuated vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab decreases effects of Ebola Zaire vaccine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Administer all age-appropriate vaccinations before starting teplizumab. Live-attenuated vaccines are not recommended within 8 weeks before teplizumab treatment, during treatment, or up to 52 weeks after treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "tisagenlecleucel decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "betibeglogene autotemcel, Ebola Zaire vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Live, attenuated vaccinations may be less effective if administered during leniolisib treatment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Injection site pain",
            "percent": "34-69.5"
        },
        {
            "name": "Headache",
            "percent": "36.9"
        },
        {
            "name": "Feverishness",
            "percent": "34.3"
        },
        {
            "name": "Muscle pain",
            "percent": "32.5"
        },
        {
            "name": "Fatigue",
            "percent": "18.5"
        },
        {
            "name": "Joint pain",
            "percent": "17.9"
        },
        {
            "name": "Injection site swelling",
            "percent": "16.5"
        },
        {
            "name": "Injection site redness",
            "percent": "11.9"
        },
        {
            "name": "Nausea",
            "percent": "8"
        },
        {
            "name": "Joint pain",
            "percent": "7"
        },
        {
            "name": "tenderness",
            "percent": "0.8-4.7"
        },
        {
            "name": "Arthritis",
            "percent": "3.6-3.8"
        },
        {
            "name": "Rash",
            "percent": "3.2"
        },
        {
            "name": "Abnormal sweating",
            "percent": "1.8"
        },
        {
            "name": "Local reactions",
            "percent": "1.5"
        },
        {
            "name": "eg",
            "percent": "0.6"
        },
        {
            "name": "redness",
            "percent": "0.4"
        },
        {
            "name": "swelling",
            "percent": "0.4"
        },
        {
            "name": "Vesicular lesions",
            "percent": null
        },
        {
            "name": "Arthropathy",
            "percent": null
        },
        {
            "name": "joint redness",
            "percent": null
        },
        {
            "name": "warmth",
            "percent": null
        },
        {
            "name": "Joint swelling",
            "percent": null
        },
        {
            "name": "Joint stiffness",
            "percent": null
        }
    ]
}